EMH.V - Emerald Health Therapeutics, Inc.

TSXV - TSXV Delayed Price. Currency in CAD
2.8100
+0.0600 (+2.18%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close2.7500
Open2.7000
Bid2.80 x 0
Ask2.82 x 0
Day's Range2.7000 - 2.8300
52 Week Range2.0400 - 9.6800
Volume375,013
Avg. Volume741,220
Market Cap397.666M
Beta (3Y Monthly)2.29
PE Ratio (TTM)N/A
EPS (TTM)-0.17
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.75
  • GlobeNewswire7 days ago

    Emerald Health Therapeutics Announces Secondary Offering

    Emerald Health Therapeutics, Inc. (EMH.V) (“Emerald” or the “Company”) today announced that Emerald Health Sciences Inc. (the “Selling Shareholder”) has entered into a share purchase agreement (the “Share Purchase Agreement”) with a single Canadian institutional accredited investor (the “Investor”) in connection with a secondary offering (the “Secondary Offering”) of common shares of the Company. Pursuant to the Share Purchase Agreement, the Investor will purchase 2,800,000 common shares of the Company (the “Secondary Shares”) from the Selling Shareholder at a price of $2.50 per Secondary Share.

  • GlobeNewswire12 days ago

    Emerald Health Therapeutics Closes Emerald Health Naturals Joint Venture

    OTCQX:EMHTF)  is pleased to announce that, further to its news releases dated April 17, 2018 and November 19, 2018, it has closed its 51:49 joint venture (the “Joint Venture”) with San Diego-based Emerald Health Bioceuticals (“EHB”), called Emerald Health Naturals (“EHN”).

  • ACCESSWIRE18 days ago

    Today's Research Reports on TSO3, Emerald Health Therapeutics, DiaMedica Therapeutics and Nuvo Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / January 4, 2019 / The Market Edge strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us ...

  • GlobeNewswirelast month

    Emerald Health Sees License Expansion of Pure Sunfarms Cannabis Production Operation to 687,000 Square Feet, one of Largest Production Capacities in Canada

    OTCQX:EMHTF) announced that its 50%-owned joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, received from Health Canada the fifth amendment to its cultivation license for its 1.1 million square foot greenhouse in Delta, BC. With an added approximately 137,000 square feet (half of Quadrant 3), the total licensed cannabis production area is approximately 687,000 square feet. The newly licensed area is expected to be fully planted by the end of this week.

  • GlobeNewswire2 months ago

    Emerald Joint Venture Receives Licenses from Health Canada to Sell Proprietary Products Supporting the Endocannabinoid System

    OTCQX: EMHTF) today announced that its joint venture, Emerald Health Naturals (“EHN”), has received product licenses and natural product numbers (NPNs) from Health Canada to sell its award-winning Endo product line of endocannabinoid-supporting nutritional products in Canada. The Endo product line has been designed to impact stress, anxiety, restless sleep, pain and other conditions using non-cannabis ingredients.

  • GlobeNewswire2 months ago

    Emerald Health Therapeutics Announces $10.8 Million Prospectus Sale

    Emerald Health Therapeutics, Inc. (EMH.V) ("Emerald" or the “Company”) has entered into a binding term sheet with a single Canadian institutional accredited investor (the “Lead Investor”) under which the Lead Investor has agreed, subject to certain customary conditions, to purchase 4,000,000 common shares of the Company (the "Common Shares") at a price of $2.70 per Common Share for gross proceeds of $10,800,000 (the "Offering"). The Offering may be increased by an additional 600,000 Common Shares for total aggregate gross proceeds of up to $12,420,000.

  • GlobeNewswire2 months ago

    Emerald Health Therapeutics Announces Executive Chairman Avtar Dhillon Appointed as President; CEO Chris Wagner Steps Down

    OTCQX:EMHTF) announced today that Dr. Avtar Dhillon, Executive Chairman, has been appointed President of Emerald and that Chris Wagner has stepped down as CEO. As Executive Chairman, Dr. Dhillon has been intimately involved in setting the Company’s strategy and overseeing its operations.

  • GlobeNewswire2 months ago

    Emerald Health Therapeutics Appoints Agro-Biotech President

    VICTORIA, British Columbia, Nov. 22, 2018 -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF) (“Emerald”) today announced that Thierry Schmidt has been.

  • GlobeNewswire2 months ago

    Emerald Health Therapeutics Receives TSX Venture Conditional Approval of Emerald Health Naturals Joint Venture

    OTCQX:EMHTF)  is pleased to announce that it has received conditional approval of the TSX Venture Exchange regarding its 51:49 joint venture (the “Joint Venture”) with San Diego-based Emerald Health Bioceuticals (“EHB”), to be called Emerald Health Naturals (“EHN”). The Company will invest $5,000,000 for 51% equity ownership of EHN.

  • ACCESSWIRE2 months ago

    Today's Research Reports on TSO3, Emerald Health Therapeutics, Emblem and BELLUS Health

    NEW YORK, NY / ACCESSWIRE / November 16, 2018 / MarketEdge Report strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with ...

  • GlobeNewswire2 months ago

    MediPharm Labs Corp. Receives Sales Licence from Health Canada

    MediPharm Labs Corp. (“MediPharm Labs” or the “Company”) (LABS.V) is pleased to announce that its wholly-owned subsidiary, MediPharm Labs Inc., has received its sales licence from Health Canada (the “Sales Licence”) pursuant to the Cannabis Act. “This Sales Licence represents a significant milestone for MediPharm Labs and a key component of our strategy to be a producer of cannabis concentrates at a globally-recognized quality standard, while also being focused on revenues, profitability and value to our shareholders, partners and constituents,” says Pat McCutcheon, co-founder and CEO of MediPharm Labs.

  • ACCESSWIRE2 months ago

    Marijuana Stocks Rally Into Thursday Morning After Sessions News: Integrated Cannabis Company (OTC: ICNAF) (CSE: ICAN), Aphria, Emerald Health

    CORAL GABLES, FL / ACCESSWIRE / November 8, 2018 / Marijuana stocks have seen a surge of attention this year. This event has been well received by the public markets as many marijuana stocks have positively reacted to this news. Sessions, who has been a staunch adversary of the legalization of cannabis, took a very conservative approach when broaching the subject.

  • GlobeNewswire2 months ago

    Emerald Health Therapeutics Fulfilling Supply Commitments with Provincial Adult-Use Cannabis Shipments

    OTCQX:EMHTF) has completed its first shipments of adult-use cannabis, fulfilling its initial supply scheduling, product, and volume commitments in British Columbia and Newfoundland and Labrador – an important milestone for the Company as it significantly ramps up production and sourcing of cannabis and cannabinoid products. Emerald products have been available in these provinces since October 31st.

  • ACCESSWIRE3 months ago

    Today's Research Reports on TSO3, Emerald Health Therapeutics, Emblem and BELLUS Health

    NEW YORK, NY / ACCESSWIRE / October 17, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • ACCESSWIRE4 months ago

    Today's Research Reports on Hemostemix, TSO3, Emerald Health Therapeutics and DiaMedica Therapeutics

    NEW YORK, NY / ACCESSWIRE / September 18, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...